Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Loncastuximab Tesirine and Epcoritamab

Phase 2Antibody–drug conjugate

UUniversität Münster

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aggressive Diffuse Large B-Cell LymphomaRecruiting

Aggressive Diffuse Large B-Cell LymphomaPhase 2

Recruiting

Timeline

Expected Milestones

Q2 2030

Phase 2Recruiting

Aggressive Diffuse Large B-Cell Lymphoma

NCT07197307

Clinical

Trials by Indication[1]

Aggressive Diffuse Large B-cell Lymphoma1 trial

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting·UUniversität Münster·Phase 2·NCT07197307·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Loncastuximab Tesirine and Epcoritamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Loncastuximab Tesirine and Epcoritamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Loncastuximab Tesirine and Epcoritamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universität Münster company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 2[1]
Company: UUniversität Münster

Related News